NRAS and melanoma: Among these, eight were identified as potential driver mutations for melanoma: ARID2 (17%), BRAF (52%), CDKN2A (13%), COL5A1 (23%), MECOM (22%), NF1 (17%), NRAS (28%), and TP53 (16%).